High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 2, 2012, Pages 287-295

  Upadhaya, Ajeet Rijal ^a   Lungrin, Irina ^a   Yamaguchi, Haruyasu ^b   Fändrich, Marcus ^c   Thal, Dietmar Rudolf ^a  

^a UNIVERSITY OF ULM   (Germany)

^b GUNMA UNIVERSITY   (Japan)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Alzheimer's disease; Amyloid protein; Fibrils; Oligomers; Protofibrils

Indexed keywords

AMYLOID BETA PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN; CHEMISTRY; CYTOLOGY; HUMAN; METABOLISM; MOLECULAR WEIGHT; PATHOLOGY; PHYSIOLOGY; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; HUMANS; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS;

EID: 84856353669     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01306.x     Document Type: Article

References (34)

1. Masters CL, Simms G, Weinman NA, et al Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985; 82: 4245-9.
2. Habicht G, Haupt C, Friedrich RP, et al Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci USA. 2007; 104: 19232-7.
3. Shankar GM, Li S, Mehta TH, et al Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14: 837-42.
4. Rosen RF, Ciliax BJ, Wingo TS, et al Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 2010; 119: 221-33.
5. Rosen RF, Tomidokoro Y, Ghiso JA, et al SDS-PAGE/immunoblot detection of Abeta multimers in human cortical tissue homogenates using antigen-epitope retrieval. J Vis Exp. 2010; 38: doi:
6. Kayed R, Head E, Thompson JL, et al Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003; 300: 486-9.
7. Spires TL, Meyer-Luehmann M, Stern EA, et al Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005; 25: 7278-87.
8. Tsai J, Grutzendler J, Duff K, et al Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004; 7: 1181-3.
9. Lesne S, Koh MT, Kotilinek L, et al A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006; 440: 352-7.
10. Thal DR, Papassotiropoulos A, Saido TC, et al Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol. 2010; 120: 169-83.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC : American Psychiatric Association; 1994.
12. The National Institute on Aging. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997; 18: S1-2.
13. Insausti R, Amaral DG. Hippocampal Formation. In: Paxinos G, Mai JK, editors. The human nervous system. 2nd ed. London : Elsevier; 2004. pp. 872-914.
14. Braak H, Alafuzoff I, Arzberger T, et al Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112: 389-404.
15. Kim KS, Miller DL, Sapienza VJ, et al Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun. 1988; 2: 121-30.
16. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-59.
17. Mirra SS, Heyman A, McKeel D, et al The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41: 479-86.
18. Thal DR, Rüb U, Schultz C, et al Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000; 59: 733-48.
19. Thal DR, Rüb U, Orantes M, et al Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58: 1791-800.
20. Utter S, Tamboli IY, Walter J, et al Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol. 2008; 67: 842-56.
21. Yamaguchi H, Sugihara S, Ogawa A, et al Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol. 1998; 95: 217-22.
22. Weidemann A, Konig G, Bunke D, et al Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989; 57: 115-26.
23. Huang X, Atwood CS, Moir RD, et al Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem. 2004; 9: 954-60.
24. Nguyen PH, Li MS, Stock G, et al Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. Proc Natl Acad Sci USA. 2007; 104: 111-6.
25. Murphy MP, Beckett TL, Ding Q, et al Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis. 2007; 27: 301-11.
26. Roher AE, Lowenson JD, Clarke S, et al beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90: 10836-40.
27. Reed MN, Hofmeister JJ, Jungbauer L, et al Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging. 2009: doi:.
28. Thal DR, Arendt T, Waldmann G, et al Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. Neurobiol Aging. 1998; 19: 517-25.
29. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008; 451: 720-4.
30. Shah P, Lal N, Leung E, et al Neuronal and Axonal Loss Are Selectively Linked to Fibrillar Amyloid-{beta} within Plaques of the Aged Primate Cerebral Cortex. Am J Pathol. 2010; 177: 325-33.
31. Serrano-Pozo A, William CM, Ferrer I, et al Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010; 133: 1312-27.
32. Capetillo-Zarate E, Staufenbiel M, Abramowski D, et al Selective vulnerability of different types of commissural neurons for amyloid beta-protein induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain. 2006; 129: 2992-3005.
33. Lambert MP, Barlow AK, Chromy BA, et al Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998; 95: 6448-53.
34. Levine H 3rd. Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. Neurobiol Aging. 1995; 16: 755-64.